462 related articles for article (PubMed ID: 26192918)
1. Paired exome analysis of Barrett's esophagus and adenocarcinoma.
Stachler MD; Taylor-Weiner A; Peng S; McKenna A; Agoston AT; Odze RD; Davison JM; Nason KS; Loda M; Leshchiner I; Stewart C; Stojanov P; Seepo S; Lawrence MS; Ferrer-Torres D; Lin J; Chang AC; Gabriel SB; Lander ES; Beer DG; Getz G; Carter SL; Bass AJ
Nat Genet; 2015 Sep; 47(9):1047-55. PubMed ID: 26192918
[TBL] [Abstract][Full Text] [Related]
2. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
3. Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma.
González MV; Artímez ML; Rodrigo L; López-Larrea C; Menéndez MJ; Alvarez V; Pérez R; Fresno MF; Pérez MJ; Sampedro A; Coto E
J Clin Pathol; 1997 Mar; 50(3):212-7. PubMed ID: 9155671
[TBL] [Abstract][Full Text] [Related]
4. Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma.
Ross-Innes CS; Becq J; Warren A; Cheetham RK; Northen H; O'Donovan M; Malhotra S; di Pietro M; Ivakhno S; He M; Weaver JMJ; Lynch AG; Kingsbury Z; Ross M; Humphray S; Bentley D; Fitzgerald RC
Nat Genet; 2015 Sep; 47(9):1038-1046. PubMed ID: 26192915
[TBL] [Abstract][Full Text] [Related]
5. Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma.
Buas MF; Levine DM; Makar KW; Utsugi H; Onstad L; Li X; Galipeau PC; Shaheen NJ; Hardie LJ; Romero Y; Bernstein L; Gammon MD; Casson AG; Bird NC; Risch HA; Ye W; Liu G; Corley DA; Blount PL; Fitzgerald RC; Whiteman DC; Wu AH; Reid BJ; Vaughan TL
Carcinogenesis; 2014 Dec; 35(12):2740-7. PubMed ID: 25280564
[TBL] [Abstract][Full Text] [Related]
6. Novel Aberrations Uncovered in Barrett's Esophagus and Esophageal Adenocarcinoma Using Whole Transcriptome Sequencing.
Maag JLV; Fisher OM; Levert-Mignon A; Kaczorowski DC; Thomas ML; Hussey DJ; Watson DI; Wettstein A; Bobryshev YV; Edwards M; Dinger ME; Lord RV
Mol Cancer Res; 2017 Nov; 15(11):1558-1569. PubMed ID: 28751461
[TBL] [Abstract][Full Text] [Related]
7. Germline variant in MSX1 identified in a Dutch family with clustering of Barrett's esophagus and esophageal adenocarcinoma.
van Nistelrooij AMJ; van Marion R; van Ijcken WFJ; de Klein A; Wagner A; Biermann K; Spaander MCW; van Lanschot JJB; Dinjens WNM; Wijnhoven BPL
Fam Cancer; 2018 Jul; 17(3):435-440. PubMed ID: 29134539
[TBL] [Abstract][Full Text] [Related]
8. Molecular clonality analysis of esophageal adenocarcinoma by multiregion sequencing of tumor samples.
van Nistelrooij AM; van Marion R; Koppert LB; Biermann K; Spaander MC; Tilanus HW; van Lanschot JJ; Wijnhoven BP; Dinjens WN
BMC Res Notes; 2017 Apr; 10(1):144. PubMed ID: 28376920
[TBL] [Abstract][Full Text] [Related]
9. Identification of Subtypes of Barrett's Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data.
Jammula S; Katz-Summercorn AC; Li X; Linossi C; Smyth E; Killcoyne S; Biasci D; Subash VV; Abbas S; Blasko A; Devonshire G; Grantham A; Wronowski F; O'Donovan M; Grehan N; Eldridge MD; Tavaré S; ; Fitzgerald RC
Gastroenterology; 2020 May; 158(6):1682-1697.e1. PubMed ID: 32032585
[TBL] [Abstract][Full Text] [Related]
10. Multistage carcinogenesis in Barrett's esophagus.
Maley CC
Cancer Lett; 2007 Jan; 245(1-2):22-32. PubMed ID: 16713672
[TBL] [Abstract][Full Text] [Related]
11. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue.
Galipeau PC; Prevo LJ; Sanchez CA; Longton GM; Reid BJ
J Natl Cancer Inst; 1999 Dec; 91(24):2087-95. PubMed ID: 10601379
[TBL] [Abstract][Full Text] [Related]
12. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
[TBL] [Abstract][Full Text] [Related]
13. Overview of major molecular alterations during progression from Barrett's esophagus to esophageal adenocarcinoma.
Kalatskaya I
Ann N Y Acad Sci; 2016 Oct; 1381(1):74-91. PubMed ID: 27415609
[TBL] [Abstract][Full Text] [Related]
14. TP53 mutations in malignant and premalignant Barrett's esophagus.
Dolan K; Walker SJ; Gosney J; Field JK; Sutton R
Dis Esophagus; 2003; 16(2):83-9. PubMed ID: 12823203
[TBL] [Abstract][Full Text] [Related]
15. Histopathology of Barrett's esophagus after ablation and endoscopic mucosal resection therapy.
Odze RD; Lauwers GY
Endoscopy; 2008 Dec; 40(12):1008-15. PubMed ID: 19065484
[TBL] [Abstract][Full Text] [Related]
16. Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis.
Chao DL; Maley CC; Wu X; Farrow DC; Galipeau PC; Sanchez CA; Paulson TG; Rabinovitch PS; Reid BJ; Spitz MR; Vaughan TL
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1935-40. PubMed ID: 17035402
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma.
Wu X; Ajani JA; Gu J; Chang DW; Tan W; Hildebrandt MA; Huang M; Wang KK; Hawk E
Cancer Prev Res (Phila); 2013 Mar; 6(3):196-205. PubMed ID: 23466817
[TBL] [Abstract][Full Text] [Related]
18. Global DNA methylation patterns in Barrett's esophagus, dysplastic Barrett's, and esophageal adenocarcinoma are associated with BMI, gender, and tobacco use.
Kaz AM; Wong CJ; Varadan V; Willis JE; Chak A; Grady WM
Clin Epigenetics; 2016; 8():111. PubMed ID: 27795744
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk.
Schulmann K; Sterian A; Berki A; Yin J; Sato F; Xu Y; Olaru A; Wang S; Mori Y; Deacu E; Hamilton J; Kan T; Krasna MJ; Beer DG; Pepe MS; Abraham JM; Feng Z; Schmiegel W; Greenwald BD; Meltzer SJ
Oncogene; 2005 Jun; 24(25):4138-48. PubMed ID: 15824739
[TBL] [Abstract][Full Text] [Related]
20. CDKN2A-p16 Deletion and Activated KRAS
Sun J; Sepulveda JL; Komissarova EV; Hills C; Seckar TD; LeFevre NM; Simonyan H; Young C; Su G; Del Portillo A; Wang TC; Sepulveda AR
Cell Mol Gastroenterol Hepatol; 2024; 17(5):769-784. PubMed ID: 38296052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
